Simulations Plus (SLP) Price-to-Projected Revenue Ratio
The expected P/S of Simulations Plus, Inc. is rising amid expanding demand for biosimulations within the biotech sector. This positive trend is based on the FDA's absolute confidence in the predictive accuracy of Simulations Plus, Inc. and the scalability of its AI platform for virtual testing. The current 4.60 metric defines this level, allowing market noise to be separated from the real value of the US exporter.
Comprehensive metric breakdowns and analytics for Simulations Plus Inc. (SLP)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt and liquidity data:
Total Debt to Equity Ratio Simulations Plus, Inc.|SLP - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Simulations Plus, Inc.|SLP - Company Aggregate Indebtedness|Debt to Book Capitalization Ratio Simulations Plus Inc.|SLP - Company Long-Term Debt|Company Current Liabilities Simulations Plus|Quick Liquidity simulations-plus.com
- business earnings and investment ratios data:
SLP - Net Financial Result|Future Profit Simulations Plus, Inc.|SLP - Company Value to Net Income|Forward P/E Multiple Simulations Plus Corp|SLP - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Simulations Plus Inc.|SLP - Operating profit before amortization|Net earnings per share (EPS TTM) Simulations Plus|SLP - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months simulations-plus.com|SLP - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Simulations Plus, Inc.
- sales and revenue indicators:
Fundamental valuation:SLP (Simulations Plus)
Simulations Plus, Inc. (SLP) leadership in AI-driven pharmaceutical modeling makes revenue a key value driver, which is assessed via the forward P/S ratio. This multiple compares market capitalization to projected sales, allowing investors to determine the premium paid for future growth. A decline in values on the Simulations Plus, Inc. (SLP) forward P/S chart signals potential business undervaluation, provided management's expansion rates remain stable.
Who Simulations Plus, Inc. competes with
Forward P/S Multiple VEEV (Veeva)|Market Cap to Expected Sales Ratio Doximity Inc (DOCS)|HQY - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Waystar Corp|CorVel Corporation (CRVL) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue PRVA|Price-to-Projected Revenue Ratio Huron|Certara Inc (CERT) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple OMCL (Omnicell Corp)|GDRX (GoodRx Gold) - Forward Price to Sales|Price-to-Projected Revenue Ratio Schrodinger, Inc. SDGR|PHR (phreesia.com) - Future Price to Revenue|OMDA - Price-to-Projected Revenue Ratio|EVH: Price-to-Projected Revenue Ratio|HSTM (HealthStream Corp) - Forward Price-to-Revenue Multiple|Definitive Corp (DH) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Consensus Cloud Solutions|agilonhealth.com (AGL) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple ABSI (Absci Corporation)|SY (So-Young International Inc) - Forward Price to Sales|Forward P/S Multiple NRC (National Research Corporation)|Market Cap to Expected Sales Ratio USA Mobility (SPOK)|OPRX - Price-to-Projected Revenue Ratio|TBRG (trubridge.com) - Market Cap to Projected Revenue|SOPH: Forward P/S Multiple|Forward Price-to-Revenue Multiple Health Catalyst Inc.|Forward Price-to-Revenue Multiple CCLD|Research Solutions Inc. (RSSS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio DLH Holdings Corp. (DLHC)|Market Cap to Expected Sales Ratio onemednet.com|Price-to-Projected Revenue Ratio Scienture SCNX|Healthcare Triangle Inc - Price-to-Projected Revenue Ratio|ISPC - Price-to-Projected Revenue Ratio|Future Price to Revenue BFRG|WORX: Forward P/S Multiple|MSPR - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple ICCT|MEDS (TRxADE HEALTH Inc) - Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple ORGS (Orgenesis Corp)|RCM (r1rcm.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Sharecare, Inc. SHCR|STRM - Forward Price-to-Revenue Multiple|Syra Health - Forward P/S Multiple|Market Cap to Future Revenue Ratio Apollo Medical Holdings|MODN: Forward P/S Multiple|Market Cap to Projected Revenue NXGN
